Testing of chemotherapeutics, targeted therapeutics and checkpoint inhibitors in neoadjuvant window-of-opportunity studies may be useful to find ways to promote BC tumor cell cytotoxicity without inducing PD-L1 or other pro-survival stress related pathways. This evidence concerns the gene CD274 and neoplasm.